Semaglutide is a globally popular long-acting GLP-1 receptor agonist. With its multiple pharmacological effects, it has become a key drug in the treatment of metabolic diseases. Through triple molecular modification, it achieves the convenience of once-weekly administration. Its core mechanisms cover three major dimensions: blood glucose regulation, weight management, and cardiovascular protection.

In clinical applications, it is approved for the treatment of type 2 diabetes. Monotherapy or combination therapy can reduce glycated hemoglobin by 1.5-1.8%. For obese/overweight people (BMI ≥ 30 or ≥ 27 with comorbidities), the average weight loss reaches 14.9%, and it can reduce the risk of major cardiovascular events by 26% at the same time. The administration methods include subcutaneous injection (with a bioavailability of 89%) and oral preparations, meeting the needs of different patients.